Patheon — Q2 2007 Earnings Presentation
13 slides from Patheon's earnings presentation, Jun 8, 2007
Slide 1: Q2 2007 Financial Results Conference Call
Q2 2007 FINANCIAL RESULTS CONFERENCE CALL June 8, 2007 10:00 a.m. (EDT) Representing Patheon z RICCARDO TRECROCE Chief Executive Officer z NICK DIPIETRO President and Chief Operating Officer z JOHN BELL Chief Financial Officer z SHELLEY JOURARD Director, Corporate Communications Patheon, Q2 2007 web
Slide 2: Agenda and Forward-looking Information
Agenda z Update on strategic initiatives – Riccardo Trecroce, CEO z Financial results – John Bell, CFO z Operations report – Nick DiPietro, President and COO z Outlook – Riccardo Trecroce, CEO z Q&A Forward-looking Information This presentation contains forward-looking statements which reflect manag
Slide 3: Strategic Update: Completed financial restructuring
STRATEGIC UPDATE Completed financial restructuring z Completed purchase by JLL Partners of US$150M of convertible preferred shares z Completed refinancing of North American and U.K. debt through new credit facilities with J.P. Morgan Securities and GE Commercial Finance …establishing a long- long-te
Slide 4: Good progress on Canadian site restructuring
Good progress on Canadian site restructuring z Niagara/Burlington divestiture − Confidential Information Memorandum issued to interested parties − Have asked for expressions of interest before end of June z York Mills-Whitby consolidation − Developing detailed transfer plans with employees, clients
Slide 5: Q2 2007 Overview: Revenues and EBITDA
Q2 2007 Overview: Revenues z Revenues down $8.9M or 5% YOY z Europe up $13.1M or 23% (11% on a CER basis) − Client carve-out volumes in Italy and France − Strong PDS growth at Swindon, U.K. z North America down $22M or 17% − Almost half of decrease attributable to lower Rx revenues at Caguas, Puerto
Slide 6: Q2 2007 Operating Results: Canada and U.S.
Q2 Operating Results: Canada z EBITDA before repositioning from Canadian commercial operations of $8.2M, down $1.5M − Lower Rx volumes YOY of a product launched in 2006 •Client was building inventory levels last year − Significant decline in OTC volumes at Whitby, but site remained profitable with s
Slide 7: Q2 2007 Operating Results: Europe and Global PDS
Q2 2007 Operating Results: Europe z European commercial manufacturing EBITDA before repositioning costs of $13.0M, up $5.6M − Strong Large Volume Parenteral volumes in Italy − Significant earnings growth at Bourgoin-Jallieu, due to full commercial production of client carve-out volumes plus new prod
Slide 8: Repositioning Costs and Refinancing Expenses
Q2 2007 Overview: Repositioning Costs Three months ended Apr. 30, 2007 Performance Enhancement Program Employee-related expenses $0.6M Consulting and professional fees 0.9M Strategic alternatives review 2.4M TOTAL $4.0M Q2 2007 Overview: Refinancing Expenses Three months ended Apr. 30, 2007 Transact
Slide 9: Operating Results: Interest, Tax Expense and Earnings (Loss)
Q2 2007 Operating Results: Interest, Tax Expense z Interest expense of $7.2M compared with $4.8M last year − Higher debt levels − Higher borrowing costs z Will have lower cash interest expense going forward under new financing arrangements z Income tax charge of $7.5M compared with $2.9M last year −
Slide 10: 1st Half 2007 Highlights
1st Half 2007 Highlights z Revenues of $352.7M, up 1% z EBITDA before repositioning costs of $47.2M (13.4% of revenues) versus $38.2M (11.0% of revenues) z Repositioning expenses of $7.7M ($6.6M after tax) z Refinancing expenses of $13.5M ($12.6M after tax) in Q2 z Excluding repositioning and refina
Slide 11: Q2 Operational Highlights and Update on PDS
Q2 Operational Highlights z North America: − Reached first commercial scale agreement for liquid fill hard capsules in Cincinnati •Product is currently in Phase II with Cincinnati PDS team z Europe: − Stronger-than-expected demand for large-volume parenteral capacity in Italy − Successful FDA PAI in
Slide 12: Outlook: Update on Puerto Rico
Update on Puerto Rico z Abbott’s Omnicef is facing generic competition − Patheon is manufacturing the authorized generic, currently benefiting from pipeline fill − Expecting a modest YOY decline in volumes in Q3, followed by more significant declines in Q4 z Significant YOY decline in volumes of Lev
Slide 13: Outlook
Outlook z Expecting Q3 revenues to be approximately the same as Q2 − Slightly higher revenues across the global network except for U.S. operations, where we expect lower revenues z Continue to expect revenues from current operations for 2007 will be comparable to 2006 Q2 2007 FINANCIAL RESULTS CONFE